Duration of Protection of Pentavalent Rotavirus Vaccination in Nicaragua

  title={Duration of Protection of Pentavalent Rotavirus Vaccination in Nicaragua},
  author={Manish M Patel and Cristina Pedreira and L{\'u}cia Helena de Oliveira and Jazmina Uma{\~n}a and Jacqueline e. Tate and Benjamin A. Lopman and Edmundo S{\'a}nchez and Martha Reyes and Juan Carlos Mercado and Alcides González and Maria Celina Perez and Angel Balmaceda and Jon Kim Andrus and Umesh D. Parashar},
  pages={e365 - e372}
OBJECTIVE: To evaluate the duration of protection of pentavaent rotavirus vaccine (RV5) against rotavirus hospitalizations in Nicaragua, a developing country in Central America. METHODS: We conducted a case-control study at 4 hospitals from 2007 through 2010, including 1016 children hospitalized with laboratory-confirmed rotavirus diarrhea, 4930 controls with nonrotavirus diarrhea (ie, “test-negative”), and 5627 controls without diarrhea. All cases and controls were aged ≥6 months and born… 

Figures and Tables from this paper

Effectiveness of Pentavalent Rotavirus Vaccine Against a Diverse Range of Circulating Strains in Nicaragua.
Introduction of RotaTeq did not result in sustained emergence of any particular strain in Nicaragua, and variation in strain-specific effectiveness was due to an age-related decline in effectiveness rather than differences in protection against the observed strains.
Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study
The monovalent rotavirus vaccine conferred high protection against hospital admission for diarrhea due toRotavirus in Bolivian children, sustained through two years of life against diverse serotypes different from the vaccine strain.
Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies
A systematic review and meta-analysis of observation studies to assess population effectiveness against acute gastroenteritis found strong evidence to further support the continued use of rotavirus vaccines.
Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis
Reductions in hospitalisations and mortality due to diarrhoea were observed in countries that adopted universal rotavirus vaccination, and the vaccines were associated with changes in genotype distribution.
Molecular Characterization Of Previously Non-Typeable Rotavirus Strains In Ghana
Ghana has over the past 20 years been involved in the surveillance of rotavirus diseases by isolating rotaviruses from diarrhoeic stools and determining the strain types as part of the build up to vaccine introduction.
Rotavirus strain surveillance for three years following the introduction of rotavirus vaccine into Belém, Brazil
G2P[4] was the predominant RV strain circulating during the first 20 months of the study, followed by G1P[8], probably reflect a natural fluctuation in RV strains over time, rather than a vaccine‐induced selective pressure.
Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial
The two-dose HRV rotavirus vaccination program significantly reduced medically attended ARD in this low-resource population in Asia and was an open-label study with an observed-only control group (no placebo).
Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial
Rotasiil provided protection against SRVGE in infants through an extended follow-up period of approximately 2 years, and protection was significant in the first year of life, when the disease burden and risk of death are highest, and against a changing pattern of rotavirus strains during the 2-year efficacy period.


Effectiveness of Pentavalent Rotavirus Vaccine Against Severe Disease
RV5 was highly effective in preventing severe rotavirus disease, even after a partial series, with protection persisting throughout the second year of life, and overall VE estimates were comparable during the first and second years of life and against AGE caused by different rotav virus strains.
Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua.
Vaccination with RV5 was associated with a lower risk of severe rotavirus diarrhea in children younger than 2 years in Nicaragua but to a lesser extent than that seen in clinical trials in industrialized countries.
Effectiveness of Pentavalent Rotavirus Vaccine in a Large Urban Population in the United States
In this setting, a complete series of RV5 was highly effective against severe rotavirus AGE and partial immunization also conferred substantial protection.
Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil.
This monovalent G1P[8] rotavirus vaccine was effective against severe G2P[4] rotvirus diarrhea among children aged 6-11 months, which suggests waning immunity.
Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study
A monovalent rotavirus vaccine was highly effective against admissions for rotav virus diarrhoea in children aged less than 2 years in El Salvador and substantially reduced the number of such admissions in this low-middle income setting.
Rotavirus disease burden, Nicaragua 2001-2005: defining the potential impact of a rotavirus vaccination program.
  • J. AmadorJosh Vasquez Manish M Patel
  • Medicine, Political Science
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2010
Uptake of rotavirus vaccine and national trends of acute gastroenteritis among children in Nicaragua.
The high rate of vaccination among age-eligible children soon after vaccine introduction in Nicaragua indicates an efficient immunization program, however, in the age group at risk of rotavirus disease, vaccine coverage during the 2007 rotav virus season had yet to reach a level sufficient for making firm conclusions about vaccine impact.
Overall 3-dose pentavalent rotavirus vaccine effectiveness was 83% to 86%; it was 92% to 93% among children 6 to 11 months of age and 78% to 84% amongChildren ≥12 months ofAge.
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
This vaccine was efficacious in preventing rotavirus gastroenteritis, decreasing severe disease and health care contacts, and the risk of intussusception was similar in vaccine and placebo recipients.